Related Experiment Video
Updated: Oct 11, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Intrapleural Hyaluronidase in Viscous Malignant Mesothelioma Pleural Effusion
Chuan T Foo1, Anna Paterson2, Adam Duckworth2
1Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England.
Abstract:
Malignant pleural effusion is common in mesothelioma. We report a case of viscous recurrent malignant mesothelioma pleural effusion. The viscosity was due to the presence of hyaluronic acid and resulted in prolonged drainage time. The use of intrapleural hyaluronidase significantly reduced fluid viscosity and drainage duration. No adverse reactions were noted. This novel case highlights the feasibility and safety of the use of intrapleural hyaluronidase in the management of hyaluronic acid-rich viscous malignant pleural effusion.
Insights
This study reports a novel treatment for viscous malignant pleural effusion in mesothelioma patients. Intrapleural hyaluronidase effectively reduced fluid viscosity and drainage time, offering a safe management option.
Area of Science:
- Oncology
- Pulmonology
- Biochemistry
Background:
- Malignant pleural effusion is a frequent complication of mesothelioma.
- Viscous effusions can complicate management and prolong treatment.
- Hyaluronic acid is a key component contributing to effusion viscosity.
Observation:
- A case of recurrent, viscous malignant pleural effusion in a mesothelioma patient is presented.
- The effusion's high viscosity was attributed to hyaluronic acid, leading to prolonged drainage.
- Standard management strategies were challenging due to the effusion's viscosity.
Findings:
- Intrapleural administration of hyaluronidase was employed to address the viscous effusion.
- Hyaluronidase treatment significantly decreased the pleural fluid viscosity.
- This resulted in a marked reduction in the duration of pleural fluid drainage.
Implications:
- Intrapleural hyaluronidase is a feasible and safe therapeutic option for hyaluronic acid-rich viscous malignant pleural effusion.
- This approach may improve patient outcomes and reduce hospital stays.
- Further research into hyaluronidase for managing complex pleural effusions is warranted.
Related Concept Videos
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
Pleural Disorders: Types and Brief Description
Pleura of the Lungs

